Gencor Pacific recently received a patent for its standardized fenugreek extract, Testofen. The U.S. patent has been granted for the product’s capacity to improve sexual function, mitigate the decline of sexual hormones, and improve sexual hormonal levels in healthy, aging males.
 
Testofen contains many bioactive compounds that have been selected and standardized to a 50% minimum content of Fenuside, the proprietary formulation of active ingredients in Testofen.
 
“We have made a significant investment into the clinical validation of Testofen, and receiving this patent further progresses our commitment and intellectual property supporting this superior fenugreek extract,” Chase Shryoc, Gencor VP of sales, said. “Testofen is the perfect addition for product formulations designed to support healthy sexual function and performance.”
 
Gencor conducted numerous double-blind placebo-controlled clinical trials to demonstrate the safety and efficacy of Testofen among healthy adult males. The studies found that Testofen is a safe and effective treatment for reducing symptoms of possible androgen deficiency, as they affect libido, sexual desire, muscle mass. It has been shown to improve sexual function and increase serum testosterone in healthy middle-aged and older men. More recently, a double-blind, randomized, placebo-controlled study found that Testofen increased muscle strength, aerobic endurance, and body composition in healthy exercising males, adding to its potential and benefits in the healthy aging marketplace.
 
More information about the patent and Testofen’s numerous clinical trials and product applications can be found at gencorpacific.com or  by contacting them directly at info@gencorpacific.com, or at 949-502-5760.